CA2199615A1 - Erythro-hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemia traits - Google Patents

Erythro-hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemia traits

Info

Publication number
CA2199615A1
CA2199615A1 CA002199615A CA2199615A CA2199615A1 CA 2199615 A1 CA2199615 A1 CA 2199615A1 CA 002199615 A CA002199615 A CA 002199615A CA 2199615 A CA2199615 A CA 2199615A CA 2199615 A1 CA2199615 A1 CA 2199615A1
Authority
CA
Canada
Prior art keywords
erythro
hydroxynonyladenine
chemically modified
modified form
adenosine deaminase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002199615A
Other languages
English (en)
French (fr)
Inventor
Elie Abushanab
Paul J. Marangos
Lewis R. Makings
Anne M. Danks
Jerzy A. Barankiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt ARD Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP96912400A priority Critical patent/EP0871449A1/en
Priority to CA002199615A priority patent/CA2199615A1/en
Priority to AU55229/96A priority patent/AU5522996A/en
Priority to PCT/US1996/001990 priority patent/WO1997028803A1/en
Publication of CA2199615A1 publication Critical patent/CA2199615A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002199615A 1996-02-12 1996-02-12 Erythro-hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemia traits Abandoned CA2199615A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP96912400A EP0871449A1 (en) 1996-02-12 1996-02-12 Hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemic traits
CA002199615A CA2199615A1 (en) 1996-02-12 1996-02-12 Erythro-hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemia traits
AU55229/96A AU5522996A (en) 1996-02-12 1996-02-12 Hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemic traits
PCT/US1996/001990 WO1997028803A1 (en) 1996-02-12 1996-02-12 Hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemic traits

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002199615A CA2199615A1 (en) 1996-02-12 1996-02-12 Erythro-hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemia traits
PCT/US1996/001990 WO1997028803A1 (en) 1996-02-12 1996-02-12 Hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemic traits

Publications (1)

Publication Number Publication Date
CA2199615A1 true CA2199615A1 (en) 1997-08-14

Family

ID=25679111

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002199615A Abandoned CA2199615A1 (en) 1996-02-12 1996-02-12 Erythro-hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemia traits

Country Status (4)

Country Link
EP (1) EP0871449A1 (enrdf_load_stackoverflow)
AU (1) AU5522996A (enrdf_load_stackoverflow)
CA (1) CA2199615A1 (enrdf_load_stackoverflow)
WO (1) WO1997028803A1 (enrdf_load_stackoverflow)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP921299A0 (en) 1999-03-15 1999-04-15 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
DE102015009609B4 (de) 2015-07-22 2024-08-22 Thomas Podzuweit Glykostimulatorische Therapie von Krebs und Metastasen: Biologisch-metabolische Krebsabwehr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1530912A (en) * 1975-02-13 1978-11-01 Wellcome Found Compositions containing 9-(2-hydroxy-3-alkyl)-adenines
US4221909A (en) * 1978-09-15 1980-09-09 Sloan-Kettering Institute For Cancer Research P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines
US5491146A (en) * 1993-01-14 1996-02-13 Cypros Pharmaceutical Corporation Hydroxylated erythro-hydroxynonyladenines and related analogs
AU6297294A (en) * 1993-02-03 1994-08-29 Gensia, Inc. Adenosine deaminase inhibitor therapies

Also Published As

Publication number Publication date
EP0871449A4 (enrdf_load_stackoverflow) 1998-10-21
AU5522996A (en) 1997-08-28
EP0871449A1 (en) 1998-10-21
WO1997028803A1 (en) 1997-08-14

Similar Documents

Publication Publication Date Title
JP4267697B2 (ja) 免疫抑制性化合物および方法
JP2688113B2 (ja) 多発性硬化症の治療のための置換アデニン誘導体を含む薬学的組成物
JP2012111764A (ja) アデノシン受容体アゴニストの治療上の使用
JP2001097973A (ja) 鏡像異性的に純粋なβ−Ｄ−（−）−ジオキソラン−ヌクレオシド
EP0774259A1 (en) New use of organic compounds
NO300014B1 (no) Kjemiske forbindelser
JPH01308267A (ja) 新規なアリステロマイシン／アデノシン誘導体類
EP4114408A1 (fr) Dérivés de nicotinamide mononucléotide et de bis-nicotinamide dinucléotide pour le traitement de l'arythmie
JPH0656877A (ja) 抗ウイルス活性および抗ガン活性を有する２’−デオキシ−２’，２’−ジフルオロ（２，６，８−置換）−プリンヌクレオシド類およびその中間体
CA2199615A1 (en) Erythro-hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemia traits
EP2771344B1 (fr) Analogues de nucleosides pour le traitement d'une infection virale, et methode d'evaluation de la sensibilite audit traitement
SG177557A1 (en) Combined preparation for use as a medicament
WO1998002166A1 (en) Adenosine deaminase inhibitors
EP0229658B1 (en) Fluorinated diaminoalkyne derivatives
EP0072760B1 (en) Fluorinated diamino-heptene and -heptyne derivatives
EP0215319A2 (en) Gem-dihalo-1,8-diamino-4-aza-octanes
JPS63208525A (ja) 心不全治療剤
Manouilov et al. Lymphatic targeting of anti-HIV nucleosides: distribution of 2′, 3′-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice
US5491146A (en) Hydroxylated erythro-hydroxynonyladenines and related analogs
EP0220409A2 (en) Gem-dihalo and tetrahalo-1,12-diamino-4,9-diaza-dodecanes
US6537974B2 (en) Method of treating arrhythmias
JPH1081685A (ja) 高い親油性および抗虚血特性を有するエリトロ−ヒドロキシノニルアデニン類似体
EP0072762B1 (en) Fluorinated diaminoalkene derivatives
WO1999003480A1 (en) Use of adenosine tri- or tetra-phosphates and their analogues for the treatment of cerebral infarction
EP0224924B1 (en) Non-aromatic fluorallylamine mao inhibitors

Legal Events

Date Code Title Description
FZDE Dead